Viewing offline content

Limited functionality available

Dismiss
Deloitte Middle East
Annotations
  • Services

    What's New

    • Deloitte175

      Join us for a celebration of 175 years of making an impact that matters.

    • Building the Resilient Organization

      2021 Deloitte Global resilience report

    • 2020 Global Gender Impact Report

      A collection of Butterfly Effect stories highlighting how our Deloitte professionals are positively impacting the lives of women and girls around the world

    • Audit & Assurance

      • Assurance
    • Consulting

      • Strategy, Analytics and M&A
      • Customer and Marketing
      • Business Operations
      • Human Capital
      • Enterprise Technology & Performance
    • Financial Advisory

      • Mergers & Acquisitions
      • Forensic
      • Real Estate
      • Turnaround & Restructuring
    • Risk Advisory

      • Strategic & Reputation Risk
      • Regulatory Risk
      • Financial Risk
      • Operational Risk
      • Cyber Risk
    • Tax

      • Global Business Tax Services
      • Indirect Tax
      • Global Employer Services
    • Deloitte Private

      • Family Enterprise
    • Legal

    • Sustainability

  • Industries

    What's New

    • Deloitte perspectives

      Leadership perspectives from across the globe.

    • Deloitte Insights App

      Our thought leadership and Dow Jones news, now at your fingertips

    • Future of Mobility

      Learn how this new reality is coming together and what it will mean for you and your industry.

    • Consumer

      • Automotive
      • Consumer Products
      • Retail, Wholesale & Distribution
      • Transportation, Hospitality & Services
    • Energy, Resources & Industrials

      • Industrial Products & Construction
      • Mining & Metals
      • Oil, Gas & Chemicals
      • Power, Utilities & Renewables
    • Financial Services

      • Banking & Capital Markets
      • Insurance
      • Investment Management
      • Real Estate
    • Government & Public Services

      • Civil Government
      • Defense, Security & Justice
      • Health & Social Care
      • Transport
    • Life Sciences & Health Care

      • Health Care
      • Life Sciences
    • MENA Sovereign Wealth Funds

    • Technology, Media & Telecommunications

      • Technology
      • Telecommunications, Media & Entertainment
  • Insights

    Deloitte Insights

    What's New

    • Deloitte Insights Magazine

      Explore the latest issue now

    • Deloitte Insights app

      Go straight to smart with daily updates on your mobile device

    • Weekly economic update

      See what's happening this week and the impact on your business

    • Strategy

      • Business Strategy & Growth
      • Digital Transformation
      • Governance & Board
      • Innovation
      • Marketing & Sales
      • Private Enterprise
    • Economy & Society

      • Economy
      • Environmental, Social, & Governance
      • Health Equity
      • Trust
      • Mobility
    • Organization

      • Operations
      • Finance & Tax
      • Risk & Regulation
      • Supply Chain
      • Smart Manufacturing
    • People

      • Leadership
      • Talent & Work
      • Diversity, Equity, & Inclusion
    • Technology

      • Data & Analytics
      • Emerging Technologies
      • Technology Management
    • Industries

      • Consumer
      • Energy, Resources, & Industrials
      • Financial Services
      • Government & Public Services
      • Life Sciences & Health Care
      • Technology, Media, & Telecommunications
    • Spotlight

      • Deloitte Insights Magazine
      • Press Room Podcasts
      • Weekly Economic Update
      • COVID-19
      • Resilience
  • Careers

    What's New

    • Millennial Survey 2022

      Gen Zs and millennials are striving for balance and advocating for change.

    • Candidate Profile

      After applying for a job in this country, you can access/update your candidate profile at any time.

    • Job Search

    • Students

    • Experienced Hires

    • Executives

    • Life at Deloitte

    • Alumni

    • Diversity and Inclusion

  • XE-EN Location: XE-English  
  • Contact us
  • XE-EN Location: XE-English  
  • Contact us
    • Dashboard
    • Saved items
    • Content feed
    • Profile/Interests
    • Account settings

Welcome back

Still not a member? Join My Deloitte

Medtech leaders prioritize technology and consumers

by Glenn Snyder , Bushra Naaz
  • Save for later
  • Download
  • Share
    • Share on Facebook
    • Share on Twitter
    • Share on Linkedin
    • Share by email
Deloitte Insights
  • Strategy
    Strategy
    Strategy
    • Business Strategy & Growth
    • Digital Transformation
    • Governance & Board
    • Innovation
    • Marketing & Sales
    • Private Enterprise
  • Economy & Society
    Economy & Society
    Economy & Society
    • Economy
    • Environmental, Social, & Governance
    • Health Equity
    • Trust
    • Mobility
  • Organization
    Organization
    Organization
    • Operations
    • Finance & Tax
    • Risk & Regulation
    • Supply Chain
    • Smart Manufacturing
  • People
    People
    People
    • Leadership
    • Talent & Work
    • Diversity, Equity, & Inclusion
  • Technology
    Technology
    Technology
    • Data & Analytics
    • Emerging Technologies
    • Technology Management
  • Industries
    Industries
    Industries
    • Consumer
    • Energy, Resources, & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • Tech, Media, & Telecom
  • Spotlight
    Spotlight
    Spotlight
    • Deloitte Insights Magazine
    • Press Room Podcasts
    • Weekly Economic Update
    • COVID-19
    • Resilience
    • XE-EN Location: XE-English  
    • Contact us
      • Dashboard
      • Saved items
      • Content feed
      • Profile/Interests
      • Account settings
    11 minute read 23 July 2020

    Medtech leaders prioritize technology and consumers Findings from a new survey and analysis of earnings calls in the first half of 2020

    11 minute read 23 July 2020
    • Glenn Snyder United States
    • Bushra Naaz United States
    • Glenn Snyder United States
    • Bushra Naaz United States
    • See more See more See less
      • Glenn Snyder United States
      • Bushra Naaz United States
    • Save for later
    • Download
    • Share
      • Share on Facebook
      • Share on Twitter
      • Share on Linkedin
      • Share by email
    • Executive summary
    • Advances in technology, the top issue facing medtech
    • Cyber and digital transformation of functions rise in list of priorities
    • How do medtech companies expect future of health developments to impact their business?
    • Companies are investing in digital capabilities, but none rate themselves as digitally mature
    • Long-term goals and the COVID-19 impact: How can companies reboot and recover?
    • Implications

    Medtech companies consider technology key to success in today’s markets, but they also rate this area as their top challenge. To bridge this gap, they need to integrate features that enable digital well-being and virtual health into their products.

    Executive summary

    Medtech companies are continuously working toward bringing innovative and breakthrough products to global markets. In our survey, we expected senior executives to highlight innovation as a major strategic focus and we found this held true—innovation, fueled by technology, is important today and will assume even greater importance in the future. When we asked about new types of offerings, responses revealed some gaps between how important some of the new technologies will be and how well-prepared companies said they felt to drive impact. To be successful in future, medtech companies should integrate features in their offerings, including digital well-being, virtual care, and remote monitoring. They should also invest in technology to transform their businesses and become more efficient and effective in the market.

    Learn more

    Explore the life sciences collection

    Learn about Deloitte's services

    Go straight to smart. Get the Deloitte Insights app

    COVID-19 has affected multiple aspects of medical technology—on the positive side, it has created demand for rapid and accurate tests and an adequate supply of personal protective equipment. The shift of some health care to virtual is an exciting opportunity. However, delayed nonurgent care has created some headwinds for the industry, and the broader economic, trade, and supply chain issues accompanying the pandemic may be felt for some time.

    This article provides insights from two sources: a survey we fielded in March and April 2020, during the COVID-19 pandemic, and text analysis of 42 medtech companies’ quarterly earnings statements in the last quarter of 2019 and first quarter of 2020 (for details, see sidebar, “Methodology”).

    Our survey found that:

    • A huge majority (88%) of respondents rated advances in technology as a top challenge, followed by policy and regulatory activity, and changes in consumer attitudes, behaviors, and spending (63%).
    • Half (50%) of the executives rated transformation of functions using digital and information technologies, cyber readiness, and economic issues as their highest priorities. Looking ahead, 69% of them said cyber readiness will be their highest priority in the next five years—signaling the need to balance digital transformation opportunities with risk preparedness. Half or more of respondents also flagged transformation of functions using digital and information technologies (56%), and economic issues (50%) as areas of focus.
    • Executives think they are most prepared to address emerging opportunities around customized treatments (81%), curative therapies (69%), and digital therapeutics (63%); only 38% said they are prepared for developments in nonpharmacological interventions—nontraditional technologies such as robotics, nanotechnology, or tissue engineering.
    • Even though leveraging digital technologies is an important strategic priority, none of the companies rated themselves as digitally mature.

    As economies and the health care industry start to recover, investments into emerging technologies (such as robotics, AR/VR) will likely gain even greater prominence—both in Medtech products and in transforming aspects of the business. The future of health (especially virtual care) and the future of work (especially virtual work) are likely to arrive sooner than we would have predicted even last year.

    Methodology

    Between March and April 2020, the Deloitte Center for Health Solutions surveyed medtech company leaders to understand their strategic priorities and the risks and challenges the industry faces. Respondents to the survey included individuals in the following roles: chief executive officer (CEO), chief operating officer (COO), chief commercial officer (CCO), and EVPs/VPs of business/corporate development of 16 medtech companies.

    In addition, we analyzed quarterly earnings statements from 39 of the largest medtech companies. The analysis was based on relevance analysis of keyword/ontology employing natural language processing to determine which themes/issues the industry thinks could have an impact on operations in the current environment.

    Advances in technology, the top issue facing medtech

    Close to 90% of respondents rated advances in technology as the top issue. This makes sense given that medtech companies are in the business of technology as a product offering, but also may be seeing opportunities to transform aspects of their business with digital investments.

    Survey finds advanced technology the top issue facing medtech, followed by policy and regulatory compliance and understanding consumer behavior

    The next most common issues cited were changing consumer attitudes and spending behavior and policy and regulatory issues (63%). Respondents rated policies affecting supply chain, privacy and data security, and tax as equally important. Policy and regulatory changes can create new opportunities —for example new payment models in Medicare—but they can also slow down innovation or make compliance more costly.1

    More than half of the respondents cited cyber and business model disruptions as top issues. A focus on innovation may call for different approaches to payment, partnerships, and commercial models, which is consistent with what we found in a recent report, Winning in the future of medtech.2 In the future, medtech companies are likely to change dramatically. The scope for collaborations and partnerships to address consumers’ demands is likely to increase. One approach that medtech companies can consider is partnering with consumer technology companies, which can help them develop offerings that keep people well (e.g. for devices for tracking biometric information) and demonstrate value to purchasers.

    Cyber and digital transformation of functions rise in list of priorities

    When we asked respondents to rank their current strategic priorities, they chose cyber and transformation of functions using digital. Cyber rises from a top strategic priority for 50% of companies right now to a top priority for 69% in five years. Respondents also expect R&D, global markets, and policy and regulatory to be more important priorities in five years than they are today.

    Text analysis finds greater emphasis on diagnostics and consumers from previous quarter

    Our analysis of the text analysis of investor meeting transcripts in the last quarter of 2019 and first quarter of 2020 showed a strong focus in both the periods on diagnostics as an area of strategic focus. Between the two periods, the words “consumer” and “elective procedures” gained salience—likely reflecting the COVID-19 pandemic. The words “restructuring” and “earnings per share” declined in prominence between the two periods.

    The research from text analytics points to an increased focus toward emerging and novel technologies, new business models, and the economic impact companies are faced with due to the pandemic. This is consistent with our survey findings.

    How do medtech companies expect future of health developments to impact their business?

    For medtech companies, as their survey responses and the text analytics show, the key to future growth will likely be understanding consumers’ needs, harnessing data, keeping people well, and taking advantages of insights and innovation coming from new technologies. Companies can win in the new health economy if they offer high value products and services—not only those that have the latest technology and clinical impact, but also that can be positioned to improve total cost of care.3 These perspectives are all consistent with our vision for the future of health.

    Our survey asked respondents to consider five statements that align with our future of health perspective for life sciences companies—some of which are threats to pharma companies and opportunities for medical technology companies. We asked about:

    • Curative therapies where companies assess new treatment regimen and develop a better understanding of cure. For this, companies may need to adopt different business models.
    • Nonpharmacological interventions that include adoption of sophisticated and nontraditional medical technologies. This could bring precise medical intervention enabled by robotics, nanotechnology, or tissue engineering.
    • Prevention and early detection to reduce prevalence of certain diseases by advancements in new technologies, and help consumers with early detection.
    • Customized treatments that include personalized treatments, utilizing patient data to provide custom solutions.
    • Digital therapeutics that could help advance transition to more care outside the hospital setting.

    Survey respondents rated nonpharmacological interventions (94%) and curative therapies and customized treatments (75%) as most impactful.

    Are they prepared to develop solutions and adapt to these changes? Medtech leaders rated their companies as well prepared to deal with growing demand for customized treatments, curative therapies, and digital therapeutics. The biggest gap between impact and preparedness was for nonpharmacological intervention (only 38% felt they were well prepared; a 56% difference in impact versus preparedness).

    Digital therapeutics is gaining traction with a shift in focus from treatment to prevention and higher use of real-time data for greater patient control. As the health sector transitions from a focus on acute intervention to one centered around prevention and wellness, these technologies will likely evolve. There is an increase in focus on technologies that track real-time data, and investment in artificial intelligence–based wellness coaching that could help enable behavior change, avoiding the need for surgery or hospitalization altogether.4

    Companies are investing in digital capabilities, but none rate themselves as digitally mature

    Opportunities for digital transformation are available throughout medtech companies’ business, from business operations such as production and enabling functions to engagement with patients, physicians, health systems, and payers to developing new products and services. Realizing each opportunity can require the capabilities of a digitally maturing organization, including an overall strategy, culture of collaboration and experimentation, and supportive leadership. Digitally maturing companies differ from those in the earlier stages of digital maturity in the way they apply digital, scale learnings, collaborate, and facilitate change. 5

    Most survey respondents believe they are close to the ideal business model employing digital, engaging talent and generating new value

    Companies believe that transforming functions using digital technologies will be of high strategic priority in the next five years. Less than half of the medtech companies responded that they are using digital technologies and capabilities to improve processes (44%). Surveyed medtech leaders reported that the key objectives for their digital investments are to reduce costs (31%), gain insights into execution of business strategy (25%), and increase demand for products (25%).

    Digital investment can help companies have a cost-effective and optimized way of executing business strategies. Going digital can help companies deal with rapidly changing technologies and improve the research and development process by strengthening the pipeline.

    Long-term goals and the COVID-19 impact: How can companies reboot and recover?

    In unstructured comments to the survey, executives flagged economic challenges arising from COVID-19 that may impact their long-term goals. The pandemic has created headwinds around reduced volume of services due to postponement of nonurgent care, and created some supply chain issues. They also mentioned general economic issues as an area of concern.

    Some of the comments they made include:

    • “COVID-19 will be a major reason to slow down growth this year.” —EVP, medtech company
    • “The first challenge is the outbreak of coronavirus all over the globe. Secondly, it is mainly about the old school vs. the new technologies that are coming up that pose a challenge. And the final challenge we see is how to map demand with supply.” —EVP, medtech company
    • “Poor analysis of future requirements for our investment. Coping with changing procedures due to COVID-19.” —COO, medtech company

    Implications

    Embrace the future of health. Many in the medtech industry are steering toward digital adoption, technological transformation, changing consumer attitudes, and business model disruptions. To achieve this, companies should consider new capabilities to win in the future of health. Being prepared with consumer-centric product portfolios, and an operating and business model that supports this, can be key to companies. Medtech companies should also consider building platforms to make sense of all the available data. Companies should also see the need to forge partnerships with hospitals to collect data on unmet needs to build nonpharmacological interventions. Medtech companies should consider what role they would like to play in the future ecosystem: data and platform provider, well-being and care delivery organization, care enabler, or elements of all three. This change in strategic focus may require leaders to identify their company’s relative strength, revisit their business strategy to cater to changing consumer demand, and identify ways to fill the gaps.

    Define strategic goals in the context of new entrants, business models, and opportunities. Medtech companies are facing new competitive threats. Their strategies should answer fundamental questions of whether or not companies want to be product or solution companies; this then leads to questions about whether they want to be in the hardware or software business moving forward. Once they decide this, they should figure out where they will get the capabilities (partnerships) and what the business model (payment) might look like. Companies are forming traditional partnerships that have focused on hardware development and partnering with consumer technology companies to be able to work on software/platforms as well.

    Virtual may be a way to go. One feature of COVID-19 has been the rapid adoption by consumers and physicians of virtual care. One might expect sustained interest in virtual care, home care, and remote monitoring services. Medtech companies might want to invest in remote monitoring solutions to improve remote access to patients, to help enable the transition to more care outside of the hospital and shift the emphasis toward prevention and maintaining well-being.

    Consider digital investments to save money, gain insight into business operations, and accelerate competitive opportunities. Medtech companies can benefit greatly by digitization—scenarios such as a network of devices, machines, and other items embedded with sensors enable interconnectivity and exchange of data—and can help connect manufacturers with suppliers. Logistics and distribution are also benefitted in avoiding costs of physical product damages, deterioration during distribution, and consequences faced due to widespread counterfeiting in the market.6

    Prepare for and address, especially cyber and economic risks, but also policy and regulatory risks. With increased digitization, medtech companies should be prepared to handle and mitigate cyber risks. The growth of connected medical devices renders medical devices to be susceptible to cybersecurity attacks. In addition, companies should stay prepared for change in any laws and regulations that could potentially lead to losses to business.

    Acknowledgments

    Project team: Madhushree Wagh and Jessica Overman assisted with the quantitative analysis and writing of the report. Alok Ranjan and Shruti Panda offered their expertise and support on the text analysis for this research. Sonal Shah from the team helped review the paper. 

    This research would not have been possible without the support from Deloitte’s Life Sciences leaders: Bill Murray, Pedro Arboleda, and Douglas Billings. The authors would also like to thank Ramani Moses, Laura DeSimio, and the many others who contributed to the success of this project.

    Cover image by: Stuart Briers

    Endnotes
      1. Sarah Thomas and Claire Boozer Cruse, Setting the stage for Medicare for All and the health coverage debate: Proposals, key policy questions, and stakeholder perspectives, Deloitte Insights, January 23, 2020. View in article

      2. Ibid. View in article

      3. Pedro Arboleda et al., Winning in the future of medtech: Novel partnerships with consumer tech to transform care delivery, September 19, 2019. View in article

      4. Ibid. View in article

      5. Greg Reh and Mike Standing, Survey finds biopharma companies lag in digital transformation: It is time for a sea change in strategy, Deloitte Insights, October 4, 2018. View in article

      6. Deloitte, The digital era in the Medtech industry: Digital supply networks and MedTech, 2018. View in article

    Show moreShow less

    Topics in this article

    Life Sciences , Life Sciences & Health Care

    Deloitte Medical Technology

    Patients, payers, and providers all look to technology to help them deliver better outcomes at lower costs. The impact of exponential technology and augmented intelligence isn’t confined to the application of care. It also shapes the relationships and market forces that drive the industry. Digital technology is inseparable from health care, and it is also central to new consumer expectations for how they will manage and receive that care. 

    Deloitte is a leader in life sciences, digital technology, and in the ways they intersect. Our solutions help life sciences companies reinvent strategies that embrace change and implementations that redefine it. Contact the authors for more information.

    Learn more
    Get in touch
    Contact
    • Glenn Snyder
    • Principal
    • Deloitte Consulting, LLP
    • gsnyder@deloitte.com
    • +1 415 699 4469

    Download Subscribe

    Related content

    img Trending

    Interactive 3 days ago

    Learn more about medtech in life sciences

    • Health tech investment trends: How are investors positioning for the future of health? Article2 years ago
    • New payment models in medtech Article2 years ago
    • Radical interoperability Video2 years ago
    • Winning in the future of medtech Article2 years ago
    • Tackling digital transformation in life sciences Article2 years ago
    • Life Sciences Collection
    Glenn Snyder

    Glenn Snyder

    Medical Technology Segment Leader

    Glenn leads Deloitte LLP's Medical Technology practice with more than 25 years of experience in medical technology, biotech, and specialty pharmaceuticals. He helps clients grow through organic and inorganic means by entering new geographic markets, and expanding into new product/service areas. Glenn also helps clients improve brand/commercial effectiveness by articulating product economic value, applying innovative pricing, updating the commercial model, and rationalizing distribution networks.

    • gsnyder@deloitte.com
    • +1 415 699 4469
    Bushra Naaz

    Bushra Naaz

    Manager | Deloitte Center for Health Solutions

    Bushra Naaz is a manager with the Deloitte Center for Health Solutions. She holds 11 years of experience in consulting, strategy, and business research in the life sciences and health care industries. At Deloitte, her research focuses on perspectives that allow clients to anticipate, prepare for, and respond to what’s coming next. Bushra holds a postgraduate business management diploma in international business from the Symbiosis Institute of Management Studies, Pune, and a bachelor’s degree in science from Ambedkar University, Agra.

    • bnaaz@deloitte.com
    • +1 678 299 8638

    Share article highlights

    See something interesting? Simply select text and choose how to share it:

    Email a customized link that shows your highlighted text.
    Copy a customized link that shows your highlighted text.
    Copy your highlighted text.

    Medtech leaders prioritize technology and consumers has been saved

    Medtech leaders prioritize technology and consumers has been removed

    An Article Titled Medtech leaders prioritize technology and consumers already exists in Saved items

     
    Forgot password

    To stay logged in, change your functional cookie settings.

    OR

    Social login not available on Microsoft Edge browser at this time.

    Connect Accounts

    Connect your social accounts

    This is the first time you have logged in with a social network.

    You have previously logged in with a different account. To link your accounts, please re-authenticate.

    Log in with an existing social network:

    To connect with your existing account, please enter your password:

    OR

    Log in with an existing site account:

    To connect with your existing account, please enter your password:

    Forgot password

    Subscribe

    to receive more business insights, analysis, and perspectives from Deloitte Insights
    ✓ Link copied to clipboard
    • Contact us
    • Search Jobs
    • Submit RFP
    Follow Deloitte Insights:
    Global office directory Office locations
    XE-EN Location: XE-English  
    About Deloitte
    • Newsroom
    • Deloitte events
    • Our blog collections
    • Press releases
    • Press contacts
    • Corporate Responsibility & Sustainability
    • Report an ethics complaint
    Services
    • Audit & Assurance
    • Consulting
    • Financial Advisory
    • Risk Advisory
    • Tax
    • Deloitte Private
    • Legal
    • Sustainability
    Industries
    • Consumer
    • Energy, Resources & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • MENA Sovereign Wealth Funds
    • Technology, Media & Telecommunications
    Careers
    • Job Search
    • Students
    • Experienced Hires
    • Executives
    • Life at Deloitte
    • Alumni
    • Diversity and Inclusion
    • About Deloitte
    • About Deloitte in the Middle East
    • Privacy
    • Terms of use
    • Cookies
    • Avature Privacy

    © 2022. See Terms of Use for more information.

    Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. Please see About Deloitte to learn more about our global network of member firms.